🤖 GLOBAL HEALTH OPTIMIZATION AGENT v3.0

🔬 Current Disease Focus:

Task Progress: 0%

👥 Active Problem Solvers

🌍 Experts collaborating globally

⚡ Current Task Assignment

🧬 Genetic Analysis

🔄 Matching experts to specific tasks

📊 Resource Allocation by Research Phase:

📚 Data Analysis

🧪 Experimental Design

🔬 Clinical Trials

💊 Treatment Development

Trial Search

Current Search Criteria:

Intervention: PT009

Found 11 matching trials

Study to Assess PT010 in Adult and Adolescent Participants With Inadequately Controlled Asthma (LOGOS)

PHASE3

This is a variable length study to evaluate the efficacy and safety of bude...

Status

Completed

Location

Research Site

Start Date

2021-03-01

Trial ID

NCT04609904

Treatments Being Tested

BGF MDI 320/28.8/9.6 μg BGF MDI 320/14.4/9.6 μg BFF MDI 320/9.6 μg BFF pMDI 320/9 μg

Study to Assess the Efficacy and Safety of PT010 Relative to PT003 and PT009 in Subjects With Moderate to Very Severe COPD (Ethos)

PHASE3

This is a randomized, double-blind, multi-center, parallel-group study to a...

Status

Completed

Location

Research Site

Start Date

2015-06-30

Trial ID

NCT02465567

Treatments Being Tested

BGF MDI 320/14.4/9.6 μg GFF MDI 14.4/9.6 μg BGF MDI 160/14.4/9.6 μg BFF MDI 320/9.6 μg

Study to Assess the Safety and Efficacy of PT010, PT003, and PT009 in Japanese Subjects With COPD Compared With Symbicort® Turbohaler®

PHASE3

A Randomized, Double-Blind, Parallel Group, 28-Week Chronic Dosing, Multi-C...

Status

Completed

Location

Research Site

Start Date

2016-08-09

Trial ID

NCT03262012

Treatments Being Tested

BGF MDI (PT010)GFF MDI (PT003)BFF MDI (PT009)Symbicort® Turbohaler® Inhalation Powder

Study to Assess Efficacy and Safety of PT009 Compared to PT005, PT008, and Symbicort® Turbuhaler® on Lung Function Over 24-Weeks in Subjects With Moderate to Very Severe COPD

PHASE3

This is a Phase III randomized, double-blind, parallel group, multi-center,...

Status

Completed

Location

Research Site

Start Date

2016-05-31

Trial ID

NCT02766608

Treatments Being Tested

BFF MDI 320/9.6 μg BFF MDI 160/9.6 μg FF MDI 9.6 μg BD MDI 320 μg Symbicort® TBH 400/12 μg BID

A Study to Assess the Efficacy and Safety of PT009 Compared to PT005 on COPD Exacerbations Over a 52-Week Period in Subjects With Moderate to Very Severe COPD (Sophos)

PHASE3

This is a Phase III randomized, double-blind, parallel group, multi-center,...

Status

Completed

Location

Research Site

Start Date

2016-04-29

Trial ID

NCT02727660

Treatments Being Tested

BFF MDI (PT009) 320/9.6 μg BFF MDI (PT009) 160/9.6 μg FF MDI (PT005) 9.6 μg

A Randomized, Double-Blind, Parallel-Group, 24-Week, Chronic-Dosing, Multi-Center Study to Assess the Efficacy and Safety of PT010, PT003, and PT009 Compared With Symbicort® Turbuhaler® (Kronos)

PHASE3

Study to Assess the Efficacy and Safety of PT010, PT003, and PT009 Compared...

Status

Completed

Location

Research Site

Start Date

2015-08-10

Trial ID

NCT02497001

Treatments Being Tested

BGF MDI 320/14.4/9.6 μg GFF MDI (PT003) 14.4/9.6 μg BFF MDI (PT009) 320/9.6 μg Symbicort® Turbuhaler® (TBH) Inhalation Powder

To Assess the Efficacy and Safety of PT010 Compared to PT009 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease

PHASE3

This is a 12-week chronic-dosing study to assess the efficacy and safety of...

Status

Withdrawn

Location

Multiple Locations

Start Date

2018-04-16

Trial ID

NCT03081247

Treatments Being Tested

BGF 320/14.4/9.6 µg MDI BFF 320/9.6 µg

Study to Assess PT010 in Adult and Adolescent Participants With Inadequately Controlled Asthma (KALOS)

PHASE3

This is a variable length study to evaluate the efficacy and safety of bude...

Status

Completed

Location

Research Site

Start Date

2020-12-15

Trial ID

NCT04609878

Treatments Being Tested

BGF MDI 320/28.8/9.6 μg BGF MDI 320/14.4/9.6 μg BFF MDI 320/9.6 μg BFF pMDI 320/9 μg

Study to Assess the Safety and Tolerability of PT010, PT009 and PT003 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease

PHASE3

Study to Assess the Safety and Tolerability of PT010, PT009 and PT003 in Su...

Status

Completed

Location

Research Site

Start Date

2015-08-10

Trial ID

NCT02536508

Treatments Being Tested

BGF MDI 320/14.4/9.6 μg GFF MDI 14.4/9.6 μg BFF MDI 320/9.6 μg

Efficacy and Safety Study of PT009, PT008, and PT005 in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

PHASE2

This is a Phase IIb, randomized, double blind, chronic dosing (28 days), fo...

Status

Completed

Location

Pearl Investigative Site

Start Date

2014-08-01

Trial ID

NCT02196077

Treatments Being Tested

BFF MDI 320/9.6 μg BFF MDI 160/9.6 μg BFF MDI 80/9.6 μg BD MDI 320 μg FF MDI 9.6 μg

Previous Next